FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine and concerns a hyperglycolised version of parental interferon type 1 wherein the hyperglycolised version of parental interferon type 1 has been modified to include at least three additional glycolised sites.
EFFECT: invention provides prolonged preservation in the subject in comparison with parental interferon type 1 that allows decreasing a dosage.
93 cl, 2 ex, 32 dwg, 12 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES RAISED AGAINST α-INTERFERON | 2002 |
|
RU2314317C2 |
| USING TYPE III PEGYLATED INTERFERONS FOR TREATING HEPATITIS C | 2009 |
|
RU2496514C2 |
| SINGLE-CHAIN TRAIL-RECEPTOR AGONIST PROTEINS | 2015 |
|
RU2699285C2 |
| VARIANTS OF GAMMA-INTERFERON POLYPEPTIDE | 2002 |
|
RU2296130C2 |
| SINGLE-STRANDED CD40 RECEPTOR AGONIST PROTEINS | 2016 |
|
RU2745801C2 |
| COMPOSITIONS AND METHODS OF TREATING DISEASES AND DISORDERS ASSOCIATING CYTOKINE SIGNAL TRANSMISSION | 2006 |
|
RU2426742C2 |
| FUSED IMMUNOGLOBULIN PROTEINS | 2008 |
|
RU2530168C2 |
| IMPROVED METHODS OF TREATING VASCULARISED MALIGNANT TUMORS | 2015 |
|
RU2692248C2 |
| VERSIONS OF GLA DOMAIN OF FACTOR VII OR VIIa | 2004 |
|
RU2373282C2 |
| MOLECULES SIMILAR TO FACTOR VII OR VIIA | 2001 |
|
RU2278123C2 |
